Colesevelam hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for colesevelam hydrochloride and what is the scope of freedom to operate?
Colesevelam hydrochloride
is the generic ingredient in two branded drugs marketed by Cosette, Alkem Labs Ltd, Glenmark Pharms Ltd, Impax, Watson Labs Inc, Beijing Tide Pharm, Bionpharma, Chartwell Rx, Dr Reddys, Impax Labs Inc, Invagen Pharms, Inventia, United Res Labs, Zhejiang Jingxin, and Zydus Pharms, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.There are ten drug master file entries for colesevelam hydrochloride. Fifteen suppliers are listed for this compound.
Summary for colesevelam hydrochloride
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 15 |
| NDAs: | 21 |
| Drug Master File Entries: | 10 |
| Finished Product Suppliers / Packagers: | 15 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Clinical Trials: | 46 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in colesevelam hydrochloride? | colesevelam hydrochloride excipients list |
| DailyMed Link: | colesevelam hydrochloride at DailyMed |
Recent Clinical Trials for colesevelam hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Puma Biotechnology, Inc. | Phase 2 |
| Pierre Fabre Laboratories | Phase 2 |
| Spanish Breast Cancer Research Group | Phase 2 |
Pharmacology for colesevelam hydrochloride
| Drug Class | Bile Acid Sequestrant |
| Mechanism of Action | Bile-acid Binding Activity |
Medical Subject Heading (MeSH) Categories for colesevelam hydrochloride
Paragraph IV (Patent) Challenges for COLESEVELAM HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| WELCHOL | Powder for Oral Suspension | colesevelam hydrochloride | 1.875 g/Packet and 3.75 g/Packet | 022362 | 1 | 2010-04-09 |
| WELCHOL | Tablets | colesevelam hydrochloride | 625 mg | 021176 | 1 | 2009-07-01 |
US Patents and Regulatory Information for colesevelam hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bionpharma | COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 208670-001 | Sep 13, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Watson Labs Inc | COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 202178-001 | Sep 1, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Chartwell Rx | COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 201354-001 | Dec 17, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Watson Labs Inc | COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 200830-001 | Sep 2, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for colesevelam hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cosette | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-002 | Oct 2, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-002 | Oct 2, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | WELCHOL | colesevelam hydrochloride | CAPSULE;ORAL | 021141-001 | May 26, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
